In a nutshell
This study investigated the role of platelet-lymphocyte ratio in predicting colorectal cancer course and outcomes. Researchers suggested that a high ratio is associated with a poorer outcome and survival.
Some background
Colorectal cancer is one of the most common cancers worldwide. Although, there have been rapid developments in diagnostic and treatment, a significant number of patients experience tumor recurrence (when the cancer comes back) and metastasis (spread to other parts of the body). Therefore, it is important to investigate ways to predict the outcomes of the cancer in order to improve the treatment plan.
Recent studies suggest that body inflammation is associated with poorer tumor outcomes. A high platelet (cells that circulate in the blood and clot to keep us from bleeding)-lymphocyte (white blood cells) ratio (PLR) is associated with inflammation. It is possible that the PLR could help predict disease outcomes. However, studies have had mixed results, with some showing no significant role for the PLR.
Methods & findings
The objective of this study was to clarify the role of the PLR in predicting colorectal cancer outcomes. This study investigated 15 other studies including information on 3991 patients.
Overall survival (OS; time from beginning the trial to death from any cause) and disease-free survival (DFS; time to recurrence or death) were determined.
Patients with an elevated PLR were 53% more likely to have a shorter OS and 68% more likely to have a shorter DFS. Patients with an increased PLR were more than twice as likely to have a more aggressive tumor and to experience recurrence.
The bottom line
This study determined that PLR is an effective factor to predict colorectal cancer outcomes and survival.
Published By :
Medicine
Date :
Jun 01, 2016
